India's Glenmark Pharma gains as AbbVie pays $700 mln for cancer drug rights

Glenmark Pharmaceuticals

09/09/2025 05:32

** Shares of Glenmark Pharma GLEN.NS rise 2% to 2,092 rupees, their highest in over a month

** Pharma co's unit Ichnos Glenmark Innovation gets $700 mln from AbbVie ABBV.N under global licensing deal for its experimental blood cancer drug ISB 2001 in North America, Europe, Japan and Greater China

** Stock rated "buy" on avg; median PT is 2,380 rupees - data compiled by LSEG

** Stock up 30% YTD

 (Reporting by Aleef Jahan in Bengaluru)

 ((aleefjahan.cs@thomsonreuters.com))